Status:
TERMINATED
Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Metastatic Kidney Cancer
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
One third of patients with kidney cancer are diagnosed in the metastatic stage, and among patients with a localized form, about 30 to 40% will develop metastases after surgery. Medical treatment of m...
Detailed Description
We propose a pilot study of CA9 serum in patients with adenocarcinoma metastatic cell treated by conventional immunotherapy and / or targeted therapy. This pilot study aims to test the CA9 serum marke...
Eligibility Criteria
Inclusion
- Conventional renal cell cancer with a pathological diagnosis
- Metastatic disease
- Consent form signed
- social security regimen affiliated
Exclusion
- Other cancer treated
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00942058
Start Date
June 1 2009
End Date
November 1 2013
Last Update
January 29 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean Perrin
Clermont-Ferrand, France, 63011
2
CHU de Saint-Etienne
Saint-Etienne, France, 42055
3
Institut Cancérologique de la Loire
Saint-Priest-en-Jarez, France, 42270